收藏切换
Pertuzumab for the treatment of HER2-positive breast cancer: a rapid health technology assessment
收藏切换
Wenjun JI1, Yangjie SHANG1, Peng MEN2, Hui WU3, Ying MA1, *
World Clinical Drug | 2024, 45(3) : 309 - 316
Less
收藏切换
World Clinical Drug | 2024, 45(3): 309-316
• Article •
Pertuzumab for the treatment of HER2-positive breast cancer: a rapid health technology assessment
Full
Wenjun JI1, Yangjie SHANG1, Peng MEN2, Hui WU3, Ying MA1, *
Affiliations
  • 1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China
  • 2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
  • 3.Department of Pharmacy, Yancheng First People's Hospital, Yancheng 224000, Jiangsu Province, China
Published: 2024-03-10 doi: 10.13683/j.wph.2024.03.012
Outline
收藏切换
Objective

To perform a rapid health technology assessment (rHTA) on the safety, effectiveness, and economy of pertuzumab in human epidermal growth factor receptor (HER)2-positive breast cancer, and to provide an evidence-based basis for clinical drug decision.

Methods

Pubmed, Cochrane Library, Embase, CNKI, Wanfang, official HTA websites were systematically searched. References were screened according to the inclusion and exclusion criterion. And the results were analyzed by data extraction and quality evaluation.

Results

20 systematic review/meta-analysis, 12 economic studies and 4 HTA were included in our study. The results of the study showed that in terms of effectiveness, pertuzumab can improve the pathologic conplete remission (pCR) and objective remission rate (ORR) of trastuzumab, pCR and disease free survival (DFS) of trastuzumab plus chemotherapy for neoadjuvant breast cancer patients. For the patients with metastatic breast cancer, pertuzumab can improve the progression-free survival (PFS) of trastuzumab, PFS, ORR, 1-year, 2-year and median overall survival (OS) of trastuzumab plus taxol, the OS of trastuzumab plus capecitabine. In terms of safety, pertuzumab had mild side effects and good safety. In terms of economy, the combination of pertuzumab was not economical both in abroad and at home.

Conclusion

Pertuzumab was effective and safe in the treatment of HER2-positive breast cancer, but the economy was poor.

pertuzumab  /  human epidermal growth factor receptor 2-positive breast cancer  /  rapid health technology assessment  /  effectiveness  /  safety  /  economy
纪汶君, 商杨婕, 门鹏, 吴慧, 马莹. 帕妥珠单抗治疗HER2阳性乳腺癌的快速卫生技术评估. 世界临床药物, 2024 , 45 (3) : 309 -316 . DOI: 10.13683/j.wph.2024.03.012
Wenjun JI, Yangjie SHANG, Peng MEN, Hui WU, Ying MA. Pertuzumab for the treatment of HER2-positive breast cancer: a rapid health technology assessment[J]. World Clinical Drug, 2024 , 45 (3) : 309 -316 . DOI: 10.13683/j.wph.2024.03.012
Year 2024 volume 45 Issue 3
16
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.03.012
  • Receive Date:2023-07-04
  • Online Date:2026-11-18
  • Published:2024-03-10
Article Data
Affiliations
History
  • Received:2023-07-04
Funding
Affiliations
    1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China
    2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
    3.Department of Pharmacy, Yancheng First People's Hospital, Yancheng 224000, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.03.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT